Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

MANKIND is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.234000
forwardPE 34.514362
debtToEquity 58.425000
earningsGrowth -0.133000
revenueGrowth 0.261000
grossMargins 0.714190
operatingMargins 0.146890
trailingEps 48.980000
forwardEps 61.700000

MANKIND's current ratio, being 1.234, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, MANKIND is well-equipped to meet its immediate financial obligations without any difficulties.
MANKIND's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

Mankind Pharma Limited's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


A recent buy bias from analysts toward MANKIND may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that MANKIND might be an appealing option for those looking to grow their wealth through stock market investments.